Effect of telcagepant on spontaneous ischemia in cardiovascular patients in a randomized study

Headache

Volumn 51, Issue 6, 2011, Pages 954-960

  Behm, Martin O ^a   Blanchard, Rebecca L ^a   Murphy, M Gail ^a   Palcza, John S ^a   Harris, Dawn E ^a   Butterfield, Kristin L ^a   Smith, William B ^b   Preston, Richard A ^c   Chodakewitz, Jeffrey A ^a   Krucoff, Mitchell W ^d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

cardiovascular; CGRP; ECG; Holter monitoring; telcagepant

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; PLACEBO; TELCAGEPANT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BREATHING RATE; CARDIAC PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; HEART RATE; HOLTER MONITORING; HUMAN; LABORATORY TEST; MALE; MOUTH TEMPERATURE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; ST SEGMENT DEPRESSION; THORAX PAIN; TREATMENT OUTCOME;

ADULT; AGED; AZEPINES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; MYOCARDIAL ISCHEMIA;

EID: 79958089912     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.01901.x     Document Type: Article

References (25)

1. 1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet. 2001; 358: 1668-1675. (Pubitemid 33124324)
2. Silberstein SD,. Migraine. Lancet. 2004; 363: 381-391. (Pubitemid 38169549)
3. Tietjen GE,. Migraine and ischaemic heart disease and stroke: Potential mechanisms and treatment implications. Cephalalgia. 2007; 27: 981-987. (Pubitemid 47125362)
4. Olesen J, Diener HC, Husstedt IW, et al,. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004; 350: 1104-1110. (Pubitemid 38298990)
5. Ho TW, Mannix LK, Fan X, et al,. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008; 70: 1304-1312. (Pubitemid 351550355)
6. Ho TW, Ferrari MD, Dodick DW, et al,. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372: 2115-2123.
7. Connor KM, Shapiro RE, Diener HC, et al,. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009; 22: 970-977.
8. Ho AP, Dahlof CGH, Silberstein SD, et al,. Randomized, controlled, trial of telcagepant over four migraine attacks. Cephalalgia. 2010; 30: 1443-1457.
9. Chan KY, Vermeersch S, de Hoon J, Villalõn CM, Maassenvandenbrink A,. Potential mechanisms of prospective antimigraine drugs: A focus on vascular (side) effects. Pharmacol Ther. 2011; 129: 332-351.
10. Chan KY, Edvinsson L, Eftekhari S, et al,. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther. 2010; 334: 746-752.
11. Lynch JJ, Regan CP, Edvinsson L, Hargreaves RJ, Kane SA,. Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries. J Cardiovasc Pharmacol. 2010; 55: 518-521.
12. Edvinsson L, Chen KY, Eftekhari S, et al,. Effect of the CGRP receptor antagonist telcagepant in human cranial arteries. Cephalalgia. 2010; 30: 1233-1240.
13. Shen Y-T, Mallee JJ, Handt LK, et al,. Effects of inhibition of α-CGRP receptors on cardiac and peripheral vascular dynamics in conscious dogs with chronic heart failure. J Cardiovasc Pharmacol. 2003; 42: 656-661. (Pubitemid 37305985)
14. Regan CP, Stump GL, Kane SA, Lynch JJ Jr,. Calcitonin gene-related peptide receptor antagonism does not affect the severity of myocardial ischemia during atrial pacing in dogs with coronary artery stenosis. J Pharmacol Exp Ther. 2009; 328: 571-578.
15. 8-37 on myocardial reactive hyperemic response in conscious dogs. Eur J Pharmacol. 2009; 623: 96-102.
16. Sinclair SR, Kane SA, Van der Schueren BJ, et al,. Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). Br J Clin Pharmacol. 2010; 69: 15-22.
17. Blanchard R, Rowe J, Palcza J, et al,. High dose telcagepant has no effect on 24-hr ambulatory blood pressure or heart rate in healthy volunteers. Headache. 2010; 50 (Suppl. 1): S35-S36 (Abstract).
18. Van der Schueren BJ, Blanchard R, Murphy MG, et al,. The potent CGRP receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men. Br J Clin Pharmacol. 2011; 71: 708-717.
19. Holter N,. New methods for heart studies: Continuous electrocardiography of active subjects over long periods is now practical. Science. 1961; 134: 1214-1220.
20. Deedwania PC, Stone PH,. Ambulatory electrocardiographic monitoring for myocardial ischemia. Curr Probl Cardiol. 2001; 26: 680-727.
21. Campeau L,. Grading of angina pectoris. Circulation. 1976; 54: 522-523.
22. Mair J, Lechleitner P, Längle T, Wiedermann C, Dienstl F, Saria A,. Plasma CGRP in acute myocardial infarction. Lancet. 1990; 335: 168. (Pubitemid 20032764)
23. Burley DS, Hamid SA, Baxter GF,. Cardioprotective actions of peptide hormones in myocardial ischemia. Heart Fail Rev. 2007; 12: 279-291. (Pubitemid 350176701)
24. Chaitman BR, Ho AP, Behm MO, et al,. The calcitonin gene-related peptide receptor antagonist teclagepant does not reduce exercise tolerance in patients with exercise induced myocardial ischemia. J Am Coll Cardiol. 2010; 55 (Suppl. 1): A100.E939 (Abstract).
25. Ho AP, Ho TW, Johnson C, et al,. Randomized controlled trial of telcagepant in the acute treatment of migraine in patients with stable coronary artery disease. Headache. 2010; 50 (Suppl. 1): 15-16.